Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.84 SEK | -0.97% | +2.22% | -54.11% |
03-01 | Sana Biotechnology Shares Rise as Q4 Non-GAAP Net Loss Narrows | MT |
03-01 | Sector Update: Health Care Stocks Edge Higher Premarket Friday | MT |
Business Summary
Number of employees: 23
Sales per Business
SEK in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Rare Diesease Patients Innovative Treatments
100.0
%
| 10 | 100.0 % | 15 | 100.0 % | +45.86% |
Sales per region
SEK in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Other European Countries
75.4
%
| 8 | 76.1 % | 12 | 75.4 % | +44.49% |
Americas
24.6
%
| 3 | 23.9 % | 4 | 24.6 % | +50.16% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Founder | 66 | 31/12/10 | |
Thomas Feldthus
CEO | Chief Executive Officer | 64 | 31/12/10 |
Jørgen Drejer
FOU | Founder | 69 | 31/12/10 |
Anita Milland
DFI | Director of Finance/CFO | 56 | 31/12/13 |
Karin Nielsen
CTO | Chief Tech/Sci/R&D Officer | 54 | - |
Chief Tech/Sci/R&D Officer | 65 | 30/04/20 | |
Corporate Officer/Principal | 52 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jørgen Drejer
FOU | Founder | 69 | 31/12/10 |
Director/Board Member | 66 | 31/12/14 | |
Anna Ljung
BRD | Director/Board Member | 44 | 18/01/18 |
Director/Board Member | 58 | 31/12/22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 132,529,086 | 80,887,377 ( 61.03 %) | 0 | 61.03 % |
Company contact information
Group companies
Name | Category and Sector |
---|---|
Saniona A/S
Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The private company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders. |
Miscellaneous Commercial Services
|
Sector
Sales per region
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-54.11% | 18.85M | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- SANION Stock
- Company SANA AB